EPISODE · Jun 30, 2021 · 21 MIN
Why Gender Issues Still Exist in Pharma/Biotech
from Your Worthy Career · host Melissa Lawrence
I’m just going to put it out there.Gender issues still exist in pharma/biotech.But why? These companies are innovative. They have some of the most talented people. It is a diverse workforce.In this episode, I’m sharing why gender issues still exist, why the well-intended solutions at the top just aren’t good enough and what we need to do instead.Key takeaways include: Challenges women face in a male dominated industryWhy there is a gap with women in leadership rolesHow to create a safe space for people to share their real experiencesWays that women can use their voices, stand up for themselves and lift other women upTools for men to be a valued part of the conversationThis episode is for everyone. There’s no man-shaming here. This is all about awareness and jumping into the deep end to have a meaningful and deeper conversation about these topics so that we can make some change...together.Mentioned in this episode:Learn more about Career Coaching with Melissa Discover if you're in the right career by taking the quizGet the Book: Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech here.Work with Me: Learn more and apply to work with me here.Love the podcast? Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram
What this episode covers
I’m just going to put it out there. Gender issues still exist in pharma/biotech. But why? These companies are innovative. They have some of the most talented people. It is a diverse workforce. In this episode, I’m sharing why gender issues still exist, why the well-intended solutions at the top just aren’t good enough and what we need to do instead. Key takeaways include: Challenges women face in a male dominated industryWhy there is a gap with women in leadership rolesH...
NOW PLAYING
Why Gender Issues Still Exist in Pharma/Biotech
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m
Nov 12, 2025 ·35m
Oct 17, 2025 ·40m